Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease

Annals of General Psychiatry

Volumn 5, Issue , 2006, Pages

  Potagas, Constantin ^a   Papageorgiou, Sokratis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PRAMIPEXOLE; QUETIAPINE; RIVASTIGMINE;

ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BEHAVIOR DISORDER; BRADYPHRENIA; BRAIN DYSFUNCTION; COGNITIVE DEFECT; COMMUNICATION DISORDER; CONFUSION; DELUSION; DEMENTIA; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FREQUENCY ANALYSIS; HALLUCINATION; HUMAN; HYPOTENSION; MEMORY DISORDER; METHODOLOGY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PERCEPTION DISORDER; PHENOMENOLOGY; PSYCHOSIS; REVIEW; SOMNOLENCE; SYMPTOMATOLOGY; VERBAL COMMUNICATION;

EID: 33748309087     PISSN: 1744859X     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-5-12     Document Type: Review

References (65)

1. Parkinson J: An essay on the shaking palsy London, Sherwood, Neely, and Jones, Paternoster Row; 1817.
2. Fenelon G, Goetz CG, Karenberg A: Hallucinations in Parkinson disease in the prelevodopa era. Neurology 2006, 66:93-98.
3. Brown RG, Marsden CD: How common is dementia in Parkinson's disease? Lancet 1984, 2:1262-5.
4. Mindham RHS: The place of dementia in Parkinson's disease: A methodologic saga. Advances in Neurology 1999, 80:403-408.
5. Cummings JL: Intellectual impairment in Parkinson's disease: Clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988, 1:24-36.
6. Mayeux R, Stern Y, Rosenstein R, Marder K, Hauser A, Cote L, Fahn S: An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988, 45:260-262.
7. Girotti F, Soliveri P, Carella F, Piccolo I, Caffarra P, Musicco M, Caraceni T: Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988, 51:1498-1502.
8. Hietanen M, Teräväinen H: The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988, 51:244-249.
9. Mayeux R, Chen J, Mirabello E, Marder K, Bell K, Dooneief G, Cote L, Stern Y: An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990, 40:1513-1517.
10. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y: A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992, 49:492-497.
11. Marder K, Tang MX, Cote L. Stern Y, Mayeux R: The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995, 52:695-701.
12. Pillon B, Dubois B, Ploska A, Agid Y: Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 1991, 41:634-643.
13. Tison F, Dartigues JF, Auriacombe S, Letenneur L, Boller F, Alperovitch A: Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995, 45:705-708.
14. Aarsland D, Tandberg E, Larsen JP, Cummings JL: Frequency of dementia in Parkinson disease. Arch Neurol 1996, 53:538-542.
15. Reid WGJ, Hely MA, Morris JG, Broe GE, Adena M, Sullivan DJ, Williamson PM: A longitudinal study of Parkinson's disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 1996, 3:327-333.
16. Hobson P, Meara J: The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 1999, 28:39-43.
17. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P: Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001, 56:730-736.
18. Aarsland D, Andersen K, Larsen JP, Lolk A: Prevalence and Characteristics of Dementia in Parkinson Disease. An 8-Year Prospective Study. Arch Neurol 2003, 60:387-392.
19. Pirozzolo FJ, Hansch EC, Mortimer JA, Webster DD, Kuskowski MA: Dementia in Parkinson's disease: a neuropsychological analysis. Brain Cogn 1982, 1:71-83.
20. Dubois B, Pillon B: Cognitive and behavioral aspects of movement disorders. In Parkinson's disease and movement disorders Edited by: Jankovic J, Tolosa E. Baltimore: Williams and Wilkins; 1998:837-858.
21. Bodis-Wollner I: Neuropsychological and perceptual deficits in Parkinson's disease. Parkinsonism and Related Disorders 2003, 9:S83-S89.
22. Lezak MD: Neuropsychological assessment 2nd edition. New York: Oxford University Press; 1995.
23. Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM, van Hilten JJ: Assessment of cognition in Parkinson's disease. Neurology 2003, 61:1222-1228.
24. Marsden CD: The mysterious motor function of the basal ganglia: The Robert Wartenberg lecture. Neurology 1982, 32:514-539.
25. Knight RG: The neuropsychology of degenerative brain diseases Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1992.
26. Alexander GE, Crutcher MD, Delong MR: Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog Brain Res 1990, 85:119-146.
27. Potagas C, Dellatolas G, Ziegler M, Leveteau J, Bathien N, Mac Leod P, Rondot P: Clinical assessment of olfactory dysfunction in Parkinson's disease. Movement Disorders 1998, 13:394-399.
28. Busenbark KL, Huber SJ, Greer G, Pahwa R, Koller WC: Olfactory function in essential tremor. Neurology 1992, 42:1631-1632.
29. Bostantjopoulou S, Katsarou Z, Papadimitriou A, Veletza V, Hatzigeorgiou G, Lees A: Clinical features of parkinsonian patients with the alpha synuclein (G209A) mutation. Mov Disord 2001, 16:1007-1013.
30. Koss E, Weiffenbach JM, Haxby JV, Friedland RP: Olfactory detection and recognition in Alzheimer's disease. Lancet 1987, 1:622.
31. Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D: Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993, 43:962-965.
32. Dubois B, Pillon B, Sternic N, Lhermitte F, Agid Y: Age-induced disturbances in Parkinson's disease. Neurology 1990, 40:38-41.
33. Albert ML, Feldman RG, Willis AL: The "subcortical dementia" of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974, 37:121-130.
34. Litvan I: Parkinsonism-Dementia Syndromes. In Parkinson's disease and movement disorders Edited by: Jankovic J, Tolosa E. Baltimore: Williams and Wilkins; 1998:819-836.
35. Jellinger KA: Morphological substrates of dementia in parkinsonism. A critical update. J Neurol Transm Suppl 1997, 51:57-82.
36. Jellinger KA, Seppi K, Wenning GK, Poewe W: Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neurol Transm Suppl General Section 2002, 109:329-339.
37. Hardy J: Dementia with Lewy bodies and Parkinson's disease are one disorder. Moving Along 2003, 5:4.
38. Lees AJ: Dementia with Lewy bodies and Parkinson's disease are two disorders. Moving Along 2003, 5:5.
39. Aarsland D, Ballard CG, Halliday G: Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004, 17:137-145.
40. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124.
41. Horimoto Y, Matsumoto M, Nkazawa H, Yuasa H, Morishita M, Akatsu H, Ikari H, Yamamoto T, Kosaka K: Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson's disease with dementia. J Neurol Sci 2003, 216:105-108.
42. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D'Olhaberriague L, Pearce RK, Agid Y: Accuracy of clinical diagnosis of Lewy body disease, Parkinson's disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998, 55:969-78.
43. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spoke EG: A 10-year study of the incidence of and factors prdicting dementia in Parkinson's disease. Neurology 2000, 54:1596-1602.
44. Emre M: Dementia associated with Parkinson's disease. Lancet Neurol 2003, 2:229-237.
45. McKeith I: Dementia in Parkinson's disease: common and treatable. Lancet Neurol 2004, 8:456-458.
46. Mayeux R, Stern Y, Rosen J, Leventhal J: Depression, intellectual impairment, and Parkinson disease. Neurology 1981, 31:645-650.
47. Starkstein SE, Preziosi TJ, Berthier ML, Bolduc PL, Mayberg HS, Robinson RG: Depression and cognitive impairment in Parkinson's disease. Brain 1989, 112:1141-1153.
48. McDonald WM, Richard IH, DeLong MR: Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003, 54:363-375.
49. Kulisevsky J: Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000, 16:365-79.
50. Marini P, Ramat S, Ginestroni A, Paganini M: Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy. Neurol Sci 2003, 24:184-5.
51. Brusa L, Bassi A, Stefani A, Pierantozzi M, Peppe A, Caramia MD, Boffa L, Ruggieri S, Stanzione P: Pramipexole in comparison to Idopa: a neuropsychological study. J Neurol Transm 2003, 110:373-380.
52. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV: Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000, 15:794-802.
53. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356:2031-2036.
54. Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002, 72:708-712.
55. Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, Johnson S: Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Genatr Cogn Disord 2004, 17(Suppl 1):40-48.
56. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R: Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005, 65:1654-1656.
57. Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001, 16:1171-1174.
58. Aarsland D, Hutchinson M, Larsen JP: Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003, 18:937-941.
59. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD: Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003, 108:368-373.
60. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
61. Leroi I, Brandt J, Reich SG, Lyketsos C, Grill S, Thompson R, Marsh L: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004, 19:1-8.
62. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992, 305:673-678.
63. Workman RH Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME: The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997, 9:594-597.
64. Aarsland D, Larsen JP, Lim NG, Tandberg E: Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999, 11:392-394.
65. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH: Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002, 63:513-515.